When comparing bone SPECT-CT diagnostic accuracy to [68Ga-PSMA] or [18F]-Choline, used in prostate cancer patient management (Janssen et al. [23], Dyrberg et al. [28], Leiris et al. [29] and Simsek et al. [30]), the results indicated that the AUC, sensitivity, and specificity of bone SPECT-CT ranged between 0.82 and 0.89, 82 and 100% and 82 and 94%, compared to 0.82 and 1.00, 93 and 100% and 95 and 100%. Here, FOLH1 is linked to prostate carcinoma.